



Orphanet Report Series

Orphan Drugs collection

January 2010

Lists of Orphan Drugs in Europe

With European orphan designation and European market authorisation

With European market authorisation without prior orphan designation in Europe

www.orpha.net



Table of contents

Methodology	3
List of orphan drugs in Europe with European orphan designation and European marketing authorisation	4
1- By tradename in alphabetical order.....	4
2- By date of MA in descending order.....	11
3- By ATC category.....	12
4- By MA holder.....	13
List of orphan drugs in Europe with European market authorisation without prior orphan designation in Europe	14

Methodology

This document provides a list of all orphan drugs that have received a European marketing authorisation (MA) at the date stated in the document. These medicinal products may now be accessible in some, though not necessarily all, European countries. In reality, the availability of a certain orphan drug in a certain country depends on the strategy of the laboratory and the decision taken by national health authorities concerning reimbursement.

List of orphan drugs in Europe with European orphan designation and European marketing authorisation

Strictly speaking, orphan drugs in Europe are medicinal products that have been granted a European orphan designation (according to the Regulation (EC) No 141/2000), and then that have been granted a European market authorisation and a positive evaluation of significant benefit.

This list is determined by cross-referencing the list of medicinal products that have been granted an orphan designation (<http://ec.europa.eu/enterprise/pharmaceuticals/register/alforphreg.htm>) with the list of medicinal products that have been granted a marketing authorisation (<http://ec.europa.eu/enterprise/pharmaceuticals/register/index.htm>).

Both lists are available on the DG Enterprise website (Directorate General) of the European Commission.

This list of drugs is arranged by tradename in alphabetical order.

The information provided here is the tradename, the name of active substance, the marketing authorisation (MA) indication, the date of MA and the MA holder.

In order to allow a multi-criteria search, three additional lists are proposed, sorted :

- by date of MA in descending order
- by ATC category
- by MA holder

List of orphan drugs in Europe with European market authorisation without prior orphan designation in Europe


By extension, the denomination “Orphan drugs” is used for medicinal products that have been granted a European marketing authorisation, but which have not been granted a European orphan designation or for which the designation was withdrawn.

These drugs may have been granted, or not, an orphan designation in another geographical area in the world.

In all cases, they have been granted a European marketing authorisation for one or more indication(s) of use for a rare disease and they appear in the DG Enterprise list of medicinal products that have been granted a marketing authorisation : <http://ec.europa.eu/enterprise/pharmaceuticals/register/index.htm>

This list of drugs is arranged by tradenames in alphabetical order.

The information provided is the tradename, the name of active substance, the “rare disease” indication of marketing authorisation (MA), the date of MA and the MA holder.

You may find additional information on each product in the tab “Orphan drugs” on Orphanet website www.orpha.net or on the EMEA website (European Medicines Agency) <http://www.emea.europa.eu>. The EMEA listing covers all marketing authorised drugs, not just orphan drugs. Orphan drugs that have been granted a European orphan designation are indicated by the logo .

Information is available in up to 22 European languages.

List of orphan drugs in Europe with European orphan designation and European marketing authorisation

1- By tradename in alphabetical order

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
AFINITOR	Everolimus (INN)	Treatment of patients with advanced renal cell carcinoma , whose disease has progressed on or after treatment with VEGF-targeted therapy	03/08/2009	Novartis Europharm Ltd
ALDURAZYME	Laronidase (INN)	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis I (MPS I) ; a [alpha]-L-iduronidase deficiency) to treat the non-neurological manifestations of the disease	10/06/2003	Genzyme Europe B.V.
ARCALYST	Rilonacept (INN)	Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) with severe symptoms, including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) , adults and children aged 12 years and older	23/10/2009	Regeneron UK Limited
ATRIANCE	Nelarabine (INN)	Treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens	22/08/2007	Glaxo Group Ltd
BUSILVEX	Busulfan (INN) (Intravenous use)	Followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option Followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients	09/07/2003	Pierre Fabre Médicament
CARBAGLU	Carglumic acid (INN)	Treatment of hyperammonaemia due to N-acetylglutamate synthase deficiency	24/01/2003	Orphan Europe S.a.r.l.
CAYSTON	Aztreonam (INN)	Suppressive therapy of chronic pulmonary infections due to <i>Pseudomonas aeruginosa</i> in patients with cystic fibrosis (CF) aged 18 years and older	21/09/2009	Gilead Sciences International Limited
CEPLENE	Histamine dihydrochloride	Treatment of adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (IL-2)	07/10/2008	EpiCept GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
CYSTADANE	Betaine anhydrous (INN)	Adjunctive treatment of homocystinuria , involving deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylene-tetrahydrofolate reductase (MTHFR), cobalamin cofactor metabolism (cbl). Cystadane should be used as supplement to other therapies such as vitamin B6 (pyridoxine), vitamin B12 (cobalamin), folate and a specific diet	15/02/2007	Orphan Europe S.a.r.l.
DIACOMIT	Stiripentol (INN)	Use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate	04/01/2007	Biocodex
ELAPRASE	Idursulfase (INN)	Long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II)	08/01/2007	Shire Human Genetic Therapies AB
EVOLTRA	Clofarabine (INN)	Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response	29/05/2006	Genzyme Europe B.V.
EXJADE	Deferasirox (INN)	Treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older. Treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups : in patients with other anaemias, in patients aged 2 to 5 years, in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells)	28/08/2006	Novartis Europharm Ltd
FABRAZYME	Recombinant human alpha-galactosidase A INN = Agalsidase beta	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency)	03/08/2001	Genzyme Europe B.V.
FIRAZYR	Icatibant acetate INN = Icatibant	Symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency)	11/07/2008	Jerini AG
GLIOLAN	5-aminolevulinic acid hydrochloride (INN)	Visualisation of malignant tissue during surgery for malignant glioma (WHO grade III and IV)	07/09/2007	Medac GmbH

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
GLIVEC	Imatinib mesilate (INN)	Treatment of : - adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment - adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis - adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy - adult patients with relapsed or refractory Ph+ ALL as monotherapy - adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements - adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR α rearrangement - adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) - adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery	07/11/2001	Novartis Europharm Ltd
ILARIS	Canakinumab (INN)	Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in adults, adolescents and children aged 4 years and older with body weight above 15 kg, including: - Muckle-Wells Syndrome (MWS), - Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA), - Severe forms of Familial Cold Autoinflammatory Syndrome (FCAS) / Familial Cold Urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash	23/10/2009	Novartis Europharm Ltd
INCRELEX	Mecasermin (INN)	Long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency (Primary IGFD)	03/08/2007	Tercica Europe Ltd
INOVELON	Rufinamide (INN)	Adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients aged 4 years and older	16/01/2007	Eisai Ltd
KUVAN	Sapropterin dihydrochloride	Treatment of hyperphenylalaninaemia (HPA) in adult and paediatric patients of 4 years of age and over with phenylketonuria (PKU) who have been shown to be responsive to such treatment Treatment of hyperphenylalaninaemia (HPA) in adult and paediatric patients with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such treatment	02/12/2008	Merck KGaA

INN - International Nonproprietary Name

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
LITAK	Cladribine (INN) (subcutaneous use)	Treatment of hairy cell leukaemia	14/04/2004	Lipomed GmbH
LYSODREN	Mitotane (INN)	Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma	28/04/2004	Laboratoire HRA Pharma
MEPACT	Mifamurtide (INN)	In children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection. It is used in combination with post-operative multi-agent chemotherapy	06/03/2009	IDM Pharma
MOZOBIL	Plerixafor (INN)	In combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly	31/07/2009	Genzyme Europe B.V.
MYOZYME	Recombinant human acid alpha-glucosidase INN = Alglucosidase alpha	Long-term enzyme replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid α -glucosidase deficiency)	29/03/2006	Genzyme Europe B.V.
NAGLAZYME	N-acetylgalactosamine 4-sulfatase INN = Galsulfase	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis VI (MPS VI; N-acetylgalactosamine 4-sulfatase deficiency; Maroteaux-Lamy syndrome)	24/01/2006	BioMarin Europe Ltd
NEXAVAR	Sorafenib tosylate Sorafenib (INN)	Treatment of hepatocellular carcinoma Treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy	19/07/2006	Bayer HealthCare AG
NPLATE	Romiplostim (INN)	Adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) in splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Nplate may be considered as second line treatment for adult non-splenectomised patients where surgery is contra-indicated	04/02/2009	Amgen Europe B.V.
NYMUSA	Caffeine citrate	Treatment of primary apnea of premature newborns	02/07/2009	Chiesi Farmaceutici SpA
ONSENAL	Celecoxib (INN)	Reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance	17/10/2003	Pfizer Ltd
ORFADIN	Nitisinone (INN)	Treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine	21/02/2005	Swedish Orphan International AB

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTORISATION INDICATION	MARKETING AUTORISATION DATE (DD/MM/YYYY)	MARKETING AUTORISATION HOLDER
PEDEA	Ibuprofen (INN)	Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age	29/07/2004	Orphan Europe S.a.r.l.
PHOTOBARR	Porfimer sodium (INN) (for use with photodynamic therapy)	Ablation of high-grade dysplasia (HGD) in patients with Barrett's Oesophagus	25/03/2004	Axcan Pharma International BV
PRIALT	Ziconotide (INN) (intraspinal use)	Treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia	21/02/2005	Eisai Ltd
REPLAGAL	Agalsidase alfa (INN)	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (alpha-galactosidase A deficiency)	03/08/2001	Shire Human Genetic Therapies AB
REVATIO	Sildenafil citrate INN = Sildenafil	Treatment of patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.	28/10/2005	Pfizer Ltd
REVLIMID	Lenalidomide (INN)	In combination with dexamethasone, treatment of multiple myeloma patients who have received at least one prior therapy	14/06/2007	Celgene Europe Ltd
SAVENE	Dexrazoxane (INN)	Treatment of anthracycline extravasation	28/07/2006	TopoTarget A/S
SIKLOS	Hydroxy-carbamide (INN)	Prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic Sickle Cell Syndrome	29/06/2007	Addmedica SAS
SOLIRIS	Eculizumab (INN)	Treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH)	20/06/2007	Alexion Europe SAS
SOMAVERT	Pegvisomant (INN)	Treatment of patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerated	13/11/2002	Pfizer Ltd
SPRYCEL	Dasatinib (INN)	Treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate Treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy	20/11/2006	Bristol-Myers Squibb Pharma EEIG
SUTENT	Sunitinib malate Sunitinib (INN)	This product was originally an orphan designated on 10 March 2005. Upon request by the MAH, Sutent has now been removed from the Community Register of Orphan Medicinal products. Cf "List of orphan drugs in Europe with European market authorisation without prior orphan designation in Europe"		

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
TASIGNA	Nilotinib (INN)	Treatment of adults with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy including imatinib	19/11/2007	Novartis Europharm Ltd
THALIDOMIDE CELGENE	Thalidomide (INN)	In combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma , aged \geq 65 years or ineligible for high dose chemotherapy	16/04/2008	Celgene Europe Ltd
THELIN	Sitaxentan sodium (INN)	Treatment of patients with pulmonary arterial hypertension classified as WHO functional class III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.	10/08/2006	Encysive (UK) Ltd
TORISEL	Temsirolimus (INN)	First-line treatment of patients with advanced renal cell carcinoma who have at least three of six prognostic risk factors Treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL)	19/11/2007	Wyeth Europa Ltd
TRACLEER	Bosentan monohydrate INN = Bosentan	Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in: Primary (idiopathic and familial) PAH, PAH secondary to scleroderma without significant interstitial pulmonary disease, PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology To reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease	15/05/2002	Actelion Registration Ltd
TRISENOX	Arsenic Trioxide (INN)	Induction of remission and consolidation in adult patients with relapsed/refractory acute promyelocytic leukaemia (APL), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid Receptor-alpha (PML/RAR-alpha) gene. Previous treatment should have included a retinoid and chemotherapy	05/03/2002	Cephalon Europe
VENTAVIS	Iloprost (INN)	Treatment of patients with primary pulmonary hypertension , classified as NYHA functional class III, to improve exercise capacity and symptoms	16/09/2003	Bayer Schering Pharma AG

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
VIDAZA	Azacitidine (INN)	Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with: -intermediate 2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS) - chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative disorder - acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification	17/12/2008	Celgene Europe Ltd
VOLIBRIS	Ambrisentan (INN)	Treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity	21/04/2008	Glaxo Group Ltd
WILZIN	Zinc acetate dihydrate (INN)	Treatment of Wilson's disease	13/10/2004	Orphan Europe S.a.r.l.
XAGRID	Anagrelide hydrochloride INN = Anagrelide	Reduction of elevated platelet counts in at risk essential thrombocythaemia patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy	11/16/2004	Shire Pharmaceutical Contracts Ltd
XYREM	Sodium oxybate (INN)	Treatment of narcolepsy with cataplexy in adult patients	10/13/2005	UCB Pharma Ltd
YONDELIS	Trabectedin (INN)	Treatment of patients with advanced soft tissue sarcoma , after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients In combination with pegylated liposomal doxorubicin (PLD), treatment of patients with relapsed platinum-sensitive ovarian cancer	9/17/2007	Pharma Mar S.A.
ZAVESCA	Miglustat (INN)	Oral treatment of mild to moderate type 1 Gaucher disease in patients for whom enzyme replacement therapy is unsuitable Treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease	11/20/2002	Actelion Registration Ltd
ZENAS	Amifampridine (INN)	Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults	23/12/2009	EUSA Pharma SAS

2- By date of MA in descending order

2009		
AFINITOR		
ARCALYST		
CAYSTON		
ILARIS		
MEPACT		
MOZOBIL		
NPLATE		
NYMUSA		
ZENAS		
2008		
CEPLENE		
FIRAZYR		
KUVAN		
THALIDOMIDE CELGENE		
VIDAZA		
VOLIBRIS		
2007		
ATRIANCE		
CYSTADANE		
DIACOMIT		
ELAPRASE		
GLIOLAN		
INCRELEX		
INOVELON		
REVLIMID		
SIKLOS		
SOLIRIS		
TASIGNA		
TORISEL		
YONDELIS		
	2006	
	EVOLTRA	
	EXJADE	
	MYOZYME	
	NAGLAZYME	
	NEXAVAR	
	SAVENE	
	SPRYCEL	
	THELIN	
	2005	
	ORFADIN	
	PRIALT	
	REVATIO	
	XYREM	
	2004	
	LITAK	
	LYSODREN	
	PEDEA	
	PHOTOBARR	
	WILZIN	
	XAGRID	
	2003	
	ALDURAZYME	
	BUSILVEX	
	CARBAGLU	
	ONSENAL	
	VENTAVIS	
	2002	
	SOMAVERT	
	TRACLEER	
	TRISENOX	
	ZAVESCA	
		2001
		FABRAZYME
		GLIVEC
		REPLAGAL

3- By ATC category

A- ALIMENTARY TRACT AND METABOLISM	J- GENERAL ANTIINFECTIVES FOR SYSTEMIC USE	N- NERVOUS SYSTEM
ALDURAZYME	CAYSTON	DIACOMIT
CARBAGLU	L- ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	INOVELON
CYSTADANE	AFINITOR	NYMUSA
ELAPRASE	ARCALYST	PRIALT
FABRAZYME	ATRIANCE	XYREM
KUVAN	BUSILVEX	ZENAS
MYOZYME	CEPLENE	V- VARIOUS
NAGLAZYME	EVOLTRA	EXJADE
ORFADIN	GLIOLAN	SAVENE
REPLAGAL	GLIVEC	
WILZIN	ILARIS	
ZAVESCA	LITAK	
B- BLOOD AND BLOOD FORMING ORGANS	LYSODREN	
NPLATE	MEPACT	
VENTAVIS	MOZOBIL	
C- CARDIOVASCULAR SYSTEM	NEXAVAR	
FIRAZYR	ONSENAL	
PEDEA	PHOTOBARR	
THELIN	REVLIMID	
TRACLEER	SIKLOS	
VOLIBRIS	SOLIRIS	
G- GENITO URINARY SYSTEM AND SEX HORMONES	SPRYCEL	
REVATIO	TASIGNA	
H- SYSTEMIC HORMONAL PREPARATIONS, EXCL, SEX HORMONES AND INSULINS	THALIDOMIDE CELGENE	
INCRELEX	TORISEL	
SOMAVERT	TRISENOX	
	VIDAZA	
	XAGRID	
	YONDELIS	

4- By MA holder

ACTELION REGISTRATION LTD	EUSA PHARMA SAS	PFIZER LTD
TRACLEER	ZENAS	ONSENAL
ZAVESCA	GENZYME EUROPE B.V.	REVATIO
ADDMEDICA SAS	ALDURAZYME	SOMAVERT
SIKLOS	EVOLTRA	PHARMA MAR S.A.
ALEXION EUROPE SAS	FABRAZYME	YONDELIS
SOLIRIS	MOZOBIL	PIERRE FABRE MÉDICAMENT
AMGEN EUROPE B.V.	MYOZYME	BUSILVEX
NPLATE	GILEAD SCIENCES INTERNATIONAL LIMITED	REGENERON UK LIMITED
AXCAN PHARMA INTERNATIONAL BV	CAYSTON	ARCALYST
PHOTOBARR	GLAXO GROUP LTD	SHIRE HUMAN GENETIC THERAPIES AB
BAYER HEALTHCARE AG	ATRIANCE	ELAPRASE
NEXAVAR	VOLIBRIS	REPLAGAL
BAYER SCHERING PHARMA AG	IDM PHARMA	SHIRE PHARMACEUTICAL CONTRACTS LTD
VENTAVIS	MEPACT	XAGRID
BIOCODEX	JERINI AG	SWEDISH ORPHAN INTERNATIONAL AB
DIACOMIT	FIRAZYR	ORFADIN
BIOMARIN EUROPE LTD	LABORATOIRE HRA PHARMA	TERCICA EUROPE LTD
NAGLAZYME	LYSODREN	INCRELEX
BRISTOL-MYERS SQUIBB PHARMA EEIG	LIPOMED GMBH	TOPOTARGET A/S
SPRYCEL	LITAK	SAVENE
CELGENE EUROPE LTD	MEDAC GMBH	UCB PHARMA LTD
REVLIMID	GLIOLAN	XYREM
THALIDOMIDE CELGENE	MERCK KGAA	WYETH EUROPA LTD
VIDAZA	KUVAN	TORISEL
CEPHALON EUROPE	NOVARTIS EUROPHARM LTD	
TRISENOX	AFINITOR	
CHIESI FARMACEUTICI SPA	EXJADE	
NYMUSA	GLIVEC	
EISAI LTD	ILARIS	
INOVELON	TASIGNA	
PRIALT	ORPHAN EUROPE S.A.R.L.	
ENCYSIVE (UK) LTD	CARBAGLU	
THELIN	CYSTADANE	
EPICEPT GMBH	PEDEA	
CEPLENE	WILZIN	

List of orphan drugs in Europe with European market authorisation without prior orphan designation in Europe

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTORISATION INDICATION	MARKETING AUTORISATION DATE (DD/MM/YYYY)	MARKETING AUTORISATION HOLDER
ADVATE	Octocog alpha (INN)	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency)	02/03/2004	Baxter AG
ADCIRCA	Tadalafil (INN)	Treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity	01/10/2008	Eli Lilly Nederland B.V.
ALIMTA	Pemetrexed (INN)	In combination with cisplatin for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma	20/09/2004	Eli Lilly Nederland B.V.
AMMONAPS	Sodium phenylbutyrate (INN)	Adjunctive therapy in the chronic management of urea cycle disorders , involving deficiencies of carbamyl phosphate synthetase, ornithine transcarbamylase, or argininosuccinate synthetase	08/12/1999	Swedish Orphan International AB
ATRYN	Antithrombin alpha (INN)	Prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency , normally given in association with heparin or low molecular weight heparin	28/07/2006	LEO Pharma A/S
BENEFIX	Recombinant coagulation Factor IX INN = Nonacog alpha	Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency)	27/08/1997	Wyeth Europa Ltd
BIOGRASTIM	Filgrastim (INN)	In patients, children or adults, with severe congenital, cyclic , or idiopathic neutropenia with an absolute neutrophil count (ANC) of 0.5 x 10 ⁹ /l, and a history of severe or recurrent infections	15/09/2008	CT Arzneimittel GmbH
CAELYX	Doxorubicin hydrochloride (pegylated liposomal)	In combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant Treatment of AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (< 200 CD4 lymphocytes/mm ³) and extensive mucocutaneous or visceral disease	21/06/1996	SP Europe

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTORISATION INDICATION	MARKETING AUTORISATION DATE (DD/MM/YYYY)	MARKETING AUTORISATION HOLDER
CEPROTIN	Human protein C (INN)	In purpura fulminans and coumarin-induced skin necrosis in patients with severe congenital protein C deficiency Short-term prophylaxis in patients with severe congenital protein C deficiency : if surgery or invasive therapy is imminent, while initiating coumarin therapy, when coumarin therapy alone is not sufficient, when coumarin therapy is not feasible	16/07/2001	Baxter AG
CEREZYME	Imiglucerase (INN)	Longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease and who exhibit clinically significant non-neurological manifestations of the disease	17/11/1997	Genzyme Europe B.V.
CYSTAGON	Mercaptamine bitartrate (INN)	Treatment of proven nephropathic cystinosis	23/06/1997	Orphan Europe S.A.R.L.
DUKORAL	Vibrio cholerae and recombinant cholera toxin B-subunit	Active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children from 2 years of age who will be visiting endemic/epidemic areas	28/04/2004	SBL Vaccin AB
ENBREL	Etanercept (INN)	Treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 4 years who have had an inadequate response to, or who have proved intolerant of, methotrexate	03/02/2000	Wyeth Europa Ltd.
ERBITUX	Cetuximab (INN)	Treatment of patients with squamous cell cancer of the head and neck , in combination with radiation therapy for locally advanced disease and in combination with platinum-based chemotherapy for recurrent and/or metastatic disease	29/06/2004	Merck KGaA
FERRIPROX	Deferiprone (INN)	Treatment of iron overload in patients with thalassaemia major when deferoxamine therapy is contraindicated or inadequate	25/08/1999	Apotex Europe B.V.
FERTAVID	Follitropin beta (INN)	Treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism	19/03/2009	Schering-Plough Europe
FILGRASTIM RATIOPHARM	Filgrastim (INN)	In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of $0.5 \times 10^9/l$, and a history of severe or recurrent infections	15/09/2008	Ratiopharm GmbH
GONAL-F	Recombinant human follicle stimulating hormone INN = Follitropin alpha	Stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human Chorionic Gonadotrophin (hCG) therapy	20/10/1995	Serono Europe Limited

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTORISATION INDICATION	MARKETING AUTORISATION DATE (DD/MM/YYYY)	MARKETING AUTORISATION HOLDER
HELIXATE NEXGEN	Octocog alpha (INN)	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency)	04/08/2000	Bayer HealthCare AG
HUMIRA	Adalimumab (INN)	In combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis , in adolescents aged 13 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs) As monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate	08/09/2003	Abbott Laboratories Ltd.
HYCANTIN	Topotecan (INN)	Treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy Treatment of patients with relapsed small cell lung cancer [SCLC] for whom re-treatment with the first-line regimen is not considered appropriate	12/11/1996	SmithKline Beecham
INOMAX	Nitric oxide (INN)	In conjunction with ventilatory support and other appropriate agents, for the treatment of newborns \geq 34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension , in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation	01/08/2001	INO Therapeutics AB
INTRONA	Interferon alpha-2b (INN)	Treatment of patients with hairy cell leukaemia Treatment of adult patients with Philadelphia chromosome or bcr/abl translocation positive chronic myelogenous leukaemia Treatment of patients with multiple myeloma , as maintenance therapy in patients who have achieved objective remission (more than 50 % reduction in myeloma protein) following initial induction chemotherapy Treatment of high tumour burden follicular lymphoma as adjunct to appropriate combination induction chemotherapy such as a CHOP-like regimen Treatment of carcinoid tumours with lymph node or liver metastases and with «carcinoid syndrome»	09/03/2000	SP Europe
IXIARO	Japanese Encephalitis Vaccine (inactivated, adsorbed)	For active immunization against Japanese encephalitis for adults	31/03/2009	Intercell AG
KEPPRA	Levetiracetam (INN)	As adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy . In the treatment of partial onset seizures with or without secondary generalisation in infants from 1 month of age with epilepsy	29/09/2000	UCB Pharma SA

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTORISATION INDICATION	MARKETING AUTORISATION DATE (DD/MM/YYYY)	MARKETING AUTORISATION HOLDER
KOGENATE BAYER	Octocog alpha (INN)	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency)	04/08/2000	Bayer HealthCare AG
MABCAMPATH	Alemtuzumab (INN)	Treatment of patients with B-cell chronic lymphocytic leukaemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate	06/07/2001	Genzyme Europe BV
MABTHERA	Rituximab (INN)	Treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy. Maintenance therapy is indicated for patients with relapsed/refractory follicular lymphoma responding to induction therapy with chemotherapy with or without MabThera. Monotherapy is indicated for treatment of patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy Treatment of patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. In combination with chemotherapy, treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia (CLL)	02/06/1998	Roche Registration Limited
NOVOSEVEN	Human recombinant coagulation Factor VIIa INN = Eptacog alpha (activated)	Treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups : in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 BU; in patients with congenital haemophilia who are expected to have a high anamnestic response to factor VIII or factor IX administration; in patients with acquired haemophilia; in patients with congenital FVII deficiency ; in patients with Glanzmann's thrombasthenia with antibodies to GP IIb - IIIa and/or HLA, and with past or present refractoriness to platelet transfusions	23/02/1996	Novo Nordisk A/S

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTORISATION INDICATION	MARKETING AUTORISATION DATE (DD/MM/YYYY)	MARKETING AUTORISATION HOLDER
NOXAFIL	Posaconazole (INN)	<p>Treatment of the fungal infections in adults:</p> <ul style="list-style-type: none"> - Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal product - Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B - Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products - Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor <p>Prophylaxis of invasive fungal infections in :</p> <ul style="list-style-type: none"> - Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections - Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections 	25/10/2005	Schering-Plough Europe
OMNITROPE	Somatropin (INN)	<p>Growth disturbance due to insufficient secretion of growth hormone (GH) and growth disturbance associated with Turner syndrome or chronic renal insufficiency.</p> <p>Prader-Willi syndrome (PWS), for improvement of growth and body composition.</p> <p>Replacement therapy in adults with pronounced growth hormone deficiency (patients with known hypothalamic pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin)</p>	12/04/2006	Sandoz GmbH
PANRETIN	Alitretinoin (INN)	<p>Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma (KS) : when lesions are not ulcerated or lymphoedematous, and treatment of visceral KS is not required, and when lesions are not responding to systemic antiretroviral therapy, and radiotherapy or chemotherapy are not appropriate</p>	11/10/2000	Eisai Ltd.

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTORISATION INDICATION	MARKETING AUTORISATION DATE (DD/MM/YYYY)	MARKETING AUTORISATION HOLDER
PRIVIGEN	Human normal immunoglobulin (IVIg)	Replacement therapy in : - Primary immunodeficiency (PID) syndromes such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia - common variable immunodeficiency - severe combined immunodeficiency - Wiskott Aldrich syndrome - Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. Immunomodulation in : - Immune thrombocytopenic purpura (ITP) , in children or adults at high risk of bleeding or prior to surgery to correct the platelet count - Guillain-Barré syndrome - Kawasaki disease	25/04/2008	CSL Behring GmbH
PUREGON	Follitropin beta (INN)	Treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism	03/05/1996	NV Organon
RATIOGRASTIM	Filgrastim (INN)	In patients, children or adults, with severe congenital, cyclic , or idiopathic neutropenia with an absolute neutrophil count (ANC) of $0.5 \times 10^9/L$, and a history of severe or recurrent infections	15/09/2008	Ratiopharm GmbH
REFACTO AF	Moroctocog alpha (INN)	Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) in adults and children of all ages, including newborns	13/04/1999	Wyeth Europa Ltd
REFLUDAN	Lepirudin (INN)	Anticoagulation in adult patients with heparin-induced thrombocytopenia (HIT) type II and thromboembolic disease mandating parenteral antithrombotic therapy	13/03/1997	Pharmion Ltd.
RILUTEK	Riluzole (INN)	To extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS)	10/06/1996	Aventis Pharma S.A.
SAMSCA	Tolvaptan (INN)	Treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH)	03/08/2009	Otsuka Pharmaceutical Europe Ltd
SUTENT	Sunitinib malate (INN)	Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance Treatment of advanced/metastatic renal cell carcinoma (MRCC)	19/07/2006	Pfizer Limited

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTORISATION INDICATION	MARKETING AUTORISATION DATE (DD/MM/YYYY)	MARKETING AUTORISATION HOLDER
TAXOTERE	Docetaxel trihydrate (INN)	In combination with cisplatin and 5-fluorouracil for the treatment of patients with metastatic gastric adenocarcinoma , including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease In combination with cisplatin and 5-fluorouracil for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck	27/11/1995	Aventis Pharma S.A.
TEMODAL	Temozolomide (INN)	Treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment Treatment of patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma , showing recurrence or progression after standard therapy	26/01/1999	SP Europe
TEVAGRASTIM	Filgrastim (INN)	In patients, children or adults, with severe congenital, cyclic , or idiopathic neutropenia with an absolute neutrophil count (ANC) of $0.5 \times 10^9/l$, and a history of severe or recurrent infections	15/09/2008	Teva Generics GmbH
VALTROPIN	Somatropin (INN)	Long-term treatment of children with growth failure due to an inadequate secretion of normal endogenous growth hormone Treatment of short stature in children with Turner syndrome , confirmed by chromosome analysis Replacement therapy in adults with pronounced growth hormone deficiency of either childhood- or adult-onset aetiology (patients with known hypothalamic-pituitary pathology and at least one additional known deficiency of a pituitary hormone not being prolactin)	24/04/2006	BioPartners GmbH
VEDROP	Tocofersolan (INN)	Indicated in vitamin E deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis , from birth (in term newborns) to 16 or 18 years of age, depending on the region	24/07/2009	Orphan Europe S.A.R.L
VELCADE	Bortezomib (INN)	In combination with melphalan and prednisone for the treatment of patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with bone marrow transplant As mono-therapy for the treatment of progressive multiple myeloma in patients who have received at least 1 prior therapy and who have already undergone or are unsuitable for bone marrow transplantation	26/04/2004	Janssen-Cilag International NV
XELODA	Capecitabine (INN)	First-line treatment of advanced gastric cancer in combination with a platinum-based regimen	02/02/2001	Roche Registration Limited

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTORISATION INDICATION	MARKETING AUTORISATION DATE (DD/MM/YYYY)	MARKETING AUTORISATION HOLDER
ZEVALIN	Ibritumomab tiuxetan (INN)	Consolidation therapy after remission induction in previously untreated patients with follicular lymphoma Treatment of adult patients with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL)	16/01/2004	Bayer Schering Pharma
ZUTECTRA	Human Hepatitis B Immunoglobulin	Prevention of hepatitis B virus (HBV) re-infection in HBV-DNA negative patients over 6 months after liver transplantation for hepatitis B induced liver failure	30/11/2009	Biotest Pharma GmbH

For any questions or comments, please contact us: contact.orphanet@inserm.fr

Editor-in-chief: Ségolène Aymé • Editor of the report : Virginie Hivert • Visual design : Céline Angin • Photography: M. Depardieu/Inserm

The correct form when quoting this document is :

« Lists of Orphan Drugs in Europe », Orphanet Report Series, *Orphan Drugs collection*, January 2010,
http://www.orpha.net/orphacom/cahiers/docs/GB/list_of_orphan_drugs_in_europe.pdf

INN - International Nonproprietary Name